Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
April 2016
-
Media Release
Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex
Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1] Seizures are the most… -
Factory foreman keeps liver’s line workers on task
A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.
-
How scientists aim to expand immunotherapy options for cancer patients
Read how NIBR and Dana-Farber scientists aim to expand immunotherapy options for patients
-
A life dedicated to fighting malaria
Lake Victoria in southwestern Kenya is on the front line in the fight against malaria, and Agnes Akoth is a key figure.
-
In The News
Beautiful Medicine: Rediscover the Power of Nature’s Exquisite Complexity
-
Media Release
Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indication
Sandoz' epoetin alfa product offering has already generated more than 400,000[1] patient years of experience worldwide EC approval expands Sandoz biosimilar offering to the healthcare community… -
Media Release
Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP
EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily… -
Featured News
Novartis and Red Cross partner to tackle chronic diseases in refugee populations
Novartis is partnering with the International Committee of the Red Cross (ICRC) to improve care and treatment for Syrian refugees in Lebanon suffering from chronic diseases.
-
Hooked on science, Jay Bradner becomes top researcher at Novartis
New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.
-
Media Release
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless...
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…
March 2016
-
Media Release
Novartis publishes updated 2015 segment financials reflecting new division structure
Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY… -
In The News
CRISPR genome editing fuels cancer drug discovery
The better we know the molecular underpinnings of a disease, the better the odds of discovering new medicines for patients. CRISPR is changing the way medicines target cancer and other diseases.
Pagination
- ‹ Previous page
- 1
- …
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- …
- 154
- › Next page
Test disclaimer...!!!